New Zealand to fund Lilly's Strattera as second-line drug
This article was originally published in Scrip
Executive Summary
New Zealand's drug subsidy agency,Pharmac, has decided to fundLilly's attention-deficit hyperactivity disorder therapy, Strattera (atomoxetine), as a second-line treatment after stimulant-type drugs have been tried.